Matricelf Ltd.

Matricelf Ltd. is an Israeli preclinical-stage biotechnology company focused on personalized regenerative medicine. The company's core mission is to restore function and independence for patients suffering from severe neurological injuries, primarily spinal cord injury, through its proprietary autologous 3D tissue engineering platform. Headquartered in Ness Ziona, Israel, Matricelf was founded in 2019 as a spin-out from Tel Aviv University.

Matricelf's key product is an autologous engineered neural tissue implant. This innovative technology utilizes induced pluripotent stem cells (iPSCs) and extracellular matrix derived from the patient's own tissues to create functional 3D neural implants. While its primary focus is on spinal cord injury, the company's regenerative medicine platform is also being developed for other medical conditions, including stroke, traumatic brain injury (TBI), myocardial infarction (MI), Parkinson's disease, age-related macular degeneration (AMD), and 3D bioprinting.

Recent notable developments include positive RNA sequencing results in March 2026, demonstrating a promising safety profile for its spinal cord implant, a crucial step towards clinical trials. The company also entered a strategic collaboration with Japan's CiRA Foundation in March 2026 to advance regenerative manufacturing and signed an agreement with Sheba Medical Center to progress towards a first-in-human clinical trial for spinal cord injury. In February 2026, Ron Mayron was appointed Active Chairman of the Board, joining CEO Gil Hakim and co-founders Alon Sinai and Prof. Tal Dvir in leadership. Matricelf anticipates performing the world's first implantation of a personalized, engineered human spinal cord in a paralyzed patient by late 2026 or early 2027.